What is the revenue of China Resources Pharmaceutical Group?
China Resources Pharmaceutical Group Limited records massive annual revenues exceeding ₹3.7 trillion (translating to over $32 billion USD in institutional tracking metrics), cementing its status as one of the largest pharmaceutical distribution and manufacturing enterprises in Asia. The healthcare conglomerate derives its robust top-line streams from extensive drug wholesale networks, retail pharmacies, and advanced pharmaceutical research operations.
Related FAQs
Yes, CSPC Pharmaceutical Group Limited is a major Chinese pharmaceutical company headquartered in Shijiazhuang City, Hebei Province, China.
Pharmaceutical stocks carry moderate-to-high levels of specific risk, primarily related to clinical trial outcomes, regulatory rejections, and patent cliffs.
The full official corporate name of the major pharmaceutical enterprise is CSPC Pharmaceutical Group Limited.
Little Caesars does not trade publicly on any stock exchange, remaining instead a privately held subsidiary corporation under its parent entity, Ilitch Holdings, Inc.
In technical data management, cybersecurity, and regulatory compliance architectures, a CSP collector refers to a specialized software component or telemetry agent designed to gather, aggregate, and monitor cloud security posture data across multi-cl...
The United States government no longer owns any equity stake in American International Group (AIG), having successfully divested all shares acquired during the massive federal rescue package implemented during the financial crisis.
China's rapidly evolving healthcare and pharmaceutical sector includes prominent domestic research-driven corporations and manufacturing leaders that supply advanced biological formulations, generic medicines, and innovative therapies.
Jiangsu Hengrui Pharmaceuticals Co., Ltd., alongside major biopharmaceutical innovators like BeiGene, stands as one of the largest domestic pharmaceutical research and manufacturing enterprises in China.